<DOC>
	<DOCNO>NCT01940120</DOCNO>
	<brief_summary>Prospective , multi-center , single arm registry . Clinical follow-up discharge , 30 day , 6 , 12 , 18 24 , month , 3 , 4 5 year . Concurrent Control ( CC ) group identify retrospectively patient screen HRR enroll ; patient survival determine 12 month . NCT00209274 Intended use Percutaneous reduction clinically significant mitral regurgitation symptomatic patient consider high risk operative mortality ( high surgical risk ) .</brief_summary>
	<brief_title>EVEREST II Pivotal Study High Risk Registry ( HRR )</brief_title>
	<detailed_description>The EVEREST II HRR single-arm prospective , multicenter clinical trial enrol high surgical risk patient . Patients consider high surgical risk either Society Thoracic Surgery ( STS ) predict operative mortality risk ≥ 12 % , surgeon investigator determine patient high risk ( ≥ 12 % predict operative mortality risk ) due presence , minimum , one follow pre-specified risk factor : - Porcelain aorta mobile ascend aortic atheroma - Post-radiation mediastinum - Previous mediastinitis - Functional MR ejection fraction ( EF ) &lt; 40 % - Over 75 year old EF &lt; 40 % - Prior re-operation patent graft - Two prior chest surgery - Hepatic cirrhosis - Three follow STS high risk factor : i. Creatinine &gt; 2.5 mg/dL ii . Prior chest surgery iii . Age 75 iv . EF &lt; 35 % Upon completion enrollment HRR , process initiated ensure patient consent participate Concurrent Control ( CC ) group place . Patients identified determine survival 12 month current standard care treatment.CC patient derive cohort patient screen enrollment HRR , yet enroll . All patient moderate-to-severe ( 3+ ) severe ( 4+ ) MR base transthoracic echocardiography ( TTE ) . To consider eligible inclusion CC group , patient classify high surgical risk use criterion use HRR . Upon follow-up clinical site , determine initially identify patient moderate-to-severe ( 3+ ) severe ( 4+ ) MR meet criterion high surgical risk . Of patient , include due ; lack Institutional Review Board ( IRB ) approval site , lack informed consent unable contact . The remain patient make CC group .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Candidates high risk arm study must meet follow inclusion criterion : Predicted procedural mortality risk calculate use STS surgical risk calculator ≥ 12 % judgment surgeon investigator patient consider high risk surgical candidate due presence one follow indication : 1 . Porcelain aorta mobile ascend aortic atheroma 2 . Postradiation mediastinum 3 . Previous mediastinitis 4 . Functional MR EF &lt; 40 5 . Over 75 year old EF &lt; 40 6 . Reoperation patent graft 7 . Two prior chest surgery 8 . Hepatic cirrhosis Three follow STS high risk factor : ) Creatinine &gt; 2.5 mg/dL ii ) Prior chest surgery iii ) Age 75 iv ) EF &lt; 35 Age 18 year old . Symptomatic moderate severe ( 3+ ) severe ( 4+ ) chronic mitral regurgitation ( MR ) judgment investigator intervention reduce MR likely provide symptomatic relief patient . MR determine define Appendix A EVEREST II study protocol . American Society Anesthesiologists ( ASA ) physical status classification ASA IV low . The primary regurgitant jet originate malcoaptation A2 P2 scallop mitral valve . Male Female . Female subject childbearing potential must negative pregnancy test within seven ( 7 ) day procedure . The subject subject 's legal representative inform nature study agree provision provide write informed consent approve Institutional Review Board respective clinical site . The subject treating physician agree subject return require postprocedure followup visit . Transseptal catheterization determine feasible treat physician . Candidates exclude study follow condition present : Evidence acute myocardial infarction prior 2 week intend treatment ( define : Q wave nonQ wave infarction creatine kinase ( CK ) enzymes ≥ two time ( 2X ) upper laboratory normal limit presence Creatine Kinase MB Isoenzyme ( CKMB ) elevate institution 's upper limit normal ) . In judgment Investigator , femoral vein accommodate 24 F catheter presence ipsilateral deep vein thrombosis ( DVT ) . Ejection fraction &lt; 20 % , and/or endsystolic dimension &gt; 60 mm define Appendix A EVEREST II protocol . Mitral valve orifice area &lt; 4.0 cm2 define Appendix A EVEREST II protocol . If leaflet flail present : 1 . Flail Width : width flail segment great equal 15 mm , define Section 4.3 Appendix A , 2 . Flail Gap : flail gap great equal 10 mm , define Section 4.3 Appendix A . If leaflet tether present : ) . Coaptation Length : vertical coaptation length le 2 mm , define Section 4.3 Appendix A. Leaflet anatomy may preclude clip implantation , proper clip position leaflet sufficient reduction MR . This may include : Evidence calcification grasp area A2 and/or P2 scallop Presence significant cleft A2 P2 scallop More one anatomic criterion dimensionally near exclusion limit Bileaflet flail severe bileaflet prolapse Lack primary secondary chordal support Hemodynamic instability define systolic pressure &lt; 90 mmHg without load reduction cardiogenic shock need inotropic support intraaortic balloon pump . Need emergent urgent surgery reason . Prior mitral valve leaflet surgery currently implant mechanical prosthetic mitral valve . Echocardiographic evidence intracardiac mass , thrombus vegetation . Active endocarditis active rheumatic heart disease leaflet degenerate rheumatic diseased ( i.e . noncompliant , perforate ) . History bleed diathesis coagulopathy subject refuse blood transfusion . Active infection require current antibiotic therapy ( temporary illness , patient may enroll 2 week discontinuation antibiotic ) . Patients must free infection prior treatment . Any required dental work complete minimum 3 week prior treatment . Intravenous drug abuse suspect inability adhere followup . Patients transesophageal echocardiography ( TEE ) contraindicate . A known hypersensitivity contraindication study In judgment Investigator , patient presence permanent pacemaker pace lead would interfere placement test device placement test device would disrupt lead . Currently participate investigational drug another device study complete primary endpoint clinically interfere current study endpoint . [ Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Mitral Valve Insufficiency</keyword>
	<keyword>Mitral Valve Regurgitation</keyword>
	<keyword>Mitral Valve Incompetence</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Mitral Insufficiency</keyword>
	<keyword>Mitral Valve</keyword>
	<keyword>MR</keyword>
	<keyword>Mitral Valve Prolapse</keyword>
	<keyword>Edge Edge ( E2E )</keyword>
	<keyword>Alfieri Technique</keyword>
	<keyword>MitraClip</keyword>
	<keyword>Functional MR</keyword>
	<keyword>Degenerative MR</keyword>
	<keyword>Echocardiogram</keyword>
	<keyword>CAD - Coronary Artery Disease</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>EVEREST</keyword>
	<keyword>EVEREST I</keyword>
	<keyword>EVEREST II</keyword>
	<keyword>REALISM</keyword>
</DOC>